Journalists Track Opioid Settlement Cash and Fees for Telehealth Visits
51视频 Health News and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
Drugs
281-300 of 1,313 results
-
The Confusing Fate of the Abortion Pill
Episode 293The legality and availability of the abortion pill mifepristone is in question after a federal judge in Texas canceled the FDA鈥檚 approval of the first drug used in the two-drug medication abortion regimen. A 5th Circuit Court of Appeals panel overruled that decision in part, saying the pill should remain available, but only under the onerous restrictions in place before 2016. Meanwhile, another federal judge in Washington state issued a ruling in a separate case that conflicts with the Texas decision, ordering the FDA not to roll back any of its restrictions on the drug. Victoria Knight of Axios, Shefali Luthra of The 19th, and Sarah Karlin-Smith of the Pink Sheet join 51视频 Health News chief Washington correspondent Julie Rovner to discuss these issues and more.
-
The Drug Company That Prospered Without Creating Any Drugs
Horizon Therapeutics, which Amgen is acquiring for about $28 billion, grew large by snapping up cheap drugs from other companies, marketing them to perfection, and jacking up prices.
By Arthur Allen -
Doctors’ Lesson for Drug Industry: Abortion Wars Are Dangerous to Ignore
The American Medical Association ducked the abortion issue for years and now sees its members鈥 professional opinions second-guessed by lawmakers and judges. PhRMA is following the same playbook.
By Julie Rovner -
Watch: Rulings on Abortion Pill Have Far-Reaching Repercussions
Sarah Varney, a senior correspondent for KHN, joins Ali Rogin of PBS NewsHour to discuss the ruling by a federal judge in Texas that threatens nationwide access to the widely used abortion drug mifepristone, and a separate ruling in Washington state that reached the opposite conclusion.
By Sarah Varney -
Gov. Newsom Wanted California to Cut Ties With Walgreens. Then Federal Law Got in the Way.
Gov. Gavin Newsom declared that California would cut ties with Walgreens after the company said it would not distribute abortion pills in some states. But federal rules make it difficult for the state to unwind its Medicaid prescription drug agreement, which paid Walgreens $1.5 billion last year.
-
States Try to Obscure Execution Details as Drugmakers Hinder Lethal Injection
Pharmaceutical companies have put the brakes on many states鈥 ability to execute prisoners using lethal injections. Lacking alternatives, states are trying to keep the public from learning details about how they carry out executions.
-
Truly Random Drug Testing: ADHD Patients Face Uneven Urine Screens and, Sometimes, Stigma
Doctors have no national standards on when to order urine tests to check whether adult ADHD patients are properly taking their prescription stimulants. Some patients are subjected to much more frequent testing than others.
-
Journalists Delve Into Insulin Costs and Prior Authorization Policy
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
-
Sen. Sanders Shows Fire, but Seeks Modest Goals, in His Debut Drug Hearing as Health Chair
The Vermont independent and former presidential candidate was all fire and brimstone at his first hearing on drug prices as head of the Senate HELP Committee. He also pursued a more modest goal of covid vaccine price reductions. It isn鈥檛 clear whether Sanders will succeed in even that, but he has put affordability front and center.
By Arthur Allen The Policy, and Politics, of Medicare Advantage
Episode 290Medicare Advantage, the private plan alternative to traditional Medicare, is embroiled in a growing controversy over whether insurers are being overpaid and what it would mean to reduce those payments. Meanwhile, even as maternal mortality in the U.S. continues to rise, providers of care to pregnant women say they鈥檙e leaving states with abortion bans that prevent them from treating pregnancy complications. Margot Sanger-Katz of The New York Times, Jessie Hellmann of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN鈥檚 chief Washington correspondent Julie Rovner to discuss these issues and more.
-
Fresh Produce Is an Increasingly Popular Prescription for Chronically Ill Patients
Fresh produce prescription programs are getting a boost in Montana as a way of helping people with chronic conditions such as diabetes and high blood pressure. The approach may be a model for other rural states to promote healthy eating in food deserts.
By Carly Graf -
Judge Signals He Could Rule to Halt Sales of Common Abortion Pill
A U.S. District Court case is being widely followed because the judge鈥檚 decision could overturn the FDA鈥檚 approval of mifepristone two decades ago. With abortion rights polling well even in red states, anti-abortion activists are increasingly turning to the courts to achieve their aims.
By Sarah Varney -
California Picks Generic Drug Company Civica to Produce Low-Cost Insulin
Gov. Gavin Newsom, who blasted pharmaceutical companies for gouging Californians, is moving ahead with state-branded insulin. He鈥檚 also eyeing other generic drugs.
By Angela Hart -
New CDC Opioid Guidelines: Too Little, Too Late for Chronic Pain Patients?
In November, the Centers for Disease Control and Prevention released new guidelines for prescribing opioids for pain, allowing physicians more flexibility. But doctors, patients, and advocates wonder if the updated standards will be too little, too late to help chronic pain patients in a country still focused on fighting the ongoing opioid crisis.
By Sam Whitehead and Andy Miller Biden Budget Touches All the Bases
Episode 288Very little in the proposed budget released by the Biden administration is likely to become law, particularly with Republicans in charge of the U.S. House. Still, the document is an important statement of the president鈥檚 policy priorities, and it鈥檚 clear health programs are among those he feels are important. Meanwhile, five women who were denied abortions when their pregnancies threatened their lives are suing Texas. Shefali Luthra of The 19th, Victoria Knight of Axios, and Margot Sanger-Katz of The New York Times join KHN鈥檚 Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Harris Meyer, who reported and wrote the two latest KHN-NPR 鈥淏ill of the Month鈥 features. Both were about families facing unexpected bills following childbirth.
-
Why Does Insulin Cost So Much? Big Pharma Isn鈥檛 the Only Player Driving Prices
Big Pharma may be moving on from squeezing diabetes patients on insulin prices, but it鈥檚 the arbitrators that jack up prices for those who can least afford them.
By Arthur Allen -
Watch: Walgreens Won’t Sell Abortion Pill in 21 States Under GOP Threat of Legal Action
Under pressure from Republican attorneys general, the nation's second-largest pharmacy chain says it will not dispense the abortion pill mifepristone.
By Sarah Varney -
Despite Pharma Claims, Illicit Drug Shipments to US Aren鈥檛 Full of Opioids. It鈥檚 Generic Viagra.
The FDA has long blocked the importation of cheap medicine, agreeing with pharmaceutical manufacturers that it opens the door to opioids. The agency鈥檚 own data shows that rarely happens.
-
Journalists Discuss Insulin Prices, Gun Violence, Distracted Driving, and More
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.